SGS Life Science Services announces new capabilities at its Mississauga, Canada, laboratory for biopharmaceutical supply chain testing
![](/46/pdcnewsitem/03/77/10/SGS.png)
Instrumentation using uses FMS for headspace oxygen analysis of biopharmaceutical container closure systems, and icIEF for analysis of charge distribution and heterogeneity in biopharmaceuticals
SGS Life Science Services has installed and validated instrumentation which uses frequency modulation spectroscopy (FMS) for headspace oxygen analysis of biopharmaceutical container closure systems, as well as imaged capillary isoelectric focusing (icIEF) for analysis of charge distribution and heterogeneity in biopharmaceuticals, at its facility in Mississauga, Canada.
FMS now forms part of SGS’s comprehensive package and container testing services, and has the advantage over traditional methods, which use dye ingress to monitor fractures within biopharmaceutical packaging, in that the test is non-destructive, reduces the variability of analysis and conserves valuable product for further testing. Oxygen detection is a more sensitive analysis method and is reproducible on fractures less than 10 microns, which limit dye-based testing.
icIEF analysis has become a key technology at the facility for determination of the charge distribution across biopharmaceutical molecules, lending additional versatility to the already strong, multi-platform capillary electrophoresis service offering. The test, which is vital for establishing charge heterogeneity during lot release and stability testing of biopharmaceuticals, is more sensitive than traditional slab gel IEF, and often provides superior resolution over traditional mobilizing icIEF or chromatographic charge profiling. It also allows more challenging samples, which are potentially difficult to focus or resolve to be analyzed, while dramatically reducing development times.
“By investing in these new services, we have the capability to provide clients with faster, more accurate results, while protecting the integrity of the supply chains of valuable biopharmaceuticals,” commented Michael Lindsay, Vice President Life Science Services, SGS Canada. “As a company, SGS is committed to investment in new technologies that benefit not only our clients directly, but also patient safety as a whole.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance